ReviewRegenerative medicine2025
Developing stem cells for corneal disease: recent developments and future perspectives.
Review in Regenerative medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Stem cell-based regenerative therapies have revolutionized ocular medicine, offering unprecedented potential to restore vision and repair damaged corneal tissues. Recent advancements have been driven by the growing demand to overcome corneal donor shortages and the complications associated with corneal transplantation. This paper provides a comprehensive review of clinical trials and regulatory approvals over the past seven years, categorized by target disease. Despite remarkable progress, significant challenges remain in ensuring safety, efficacy, and economic viability, necessitating rigorous characterization, global standardization, and ethical considerations. Future directions include leveraging gene-editing technologies, personalized medicine, and integrated regenerative approaches to optimize therapeutic outcomes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.